ASAP Research Clinic
Patients have the opportunity to participate in clinical trials through the A.S.A.P. Research division headed by John M. Fahrenholz, M.D. The benefits of participation in a clinical research study are:
The research data gathered helps determine further study of the drug and its ultimate efficacy.
Patients may receive some symptomatic relief due to a new medication not yet on the market.
Medications, diagnostic testing, clinic visits and disease education can be at no charge to the patient.
There may be some monetary payment for the patient's participation.
The A.S.A.P. Research Clinic is located on the first floor, in Suite 120. For more information, you can contact us at (615) 936-5764.
Asthma/Allergy Trials that are currently enrolling:
Ception Protocol# RES-5-0010 “An Efficacy and Safety Study of Reslizumab (CTX55700) in the Treatment of Poorly Controlled Asthma in Subjects with Eosinophilic Airway Inflammation”
Genentech Protocol Q3662g “A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Xolair® in Subjects with Moderate to Severe Persistent Asthma Who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists.”
Rheumatoid Arthritis Trials that are currently enrolling:
Genentech Protocol U3924g “An Open-Label, Prospective Study of the Safety of Rituximab in
Combination with Other Disease Modifying Anti‑Rheumatic Drugs in Subjects with Active Rheumatoid
Arthritis – Roche Protocol ML21136: “A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of Tocilizumab (TCZ) versus placebo in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis (RA)”
Ongoing Trials that are closed to enrollment:
Accentia Protocol ACC-05-01 “A prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of intranasal amphotericin B suspension in patients with refractory, postsurgical chronic sinusitis (CS).”
Altana Protocol BY217/M2-125 “Effect of roflumilast on exacerbation rate in patients with COPD. A 52 week, double-blind study with 500µg roflumilast once daily versus placebo.”
Amgen Protocol 20060161 “A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma.”
Boehringer Ingelheim Protocol 1012.56 “A comparison of ipratropium bromide/salbutamol delivered by the Respimat® inhaler to COMBIVENT® Inhalation Aerosol and ipratropium bromide delivered by the Respimat® in a 12-week, doubleblind, safety and efficacy study in adults with chronic obstructive pulmonary disease.”
Greer Protocol SLIT07-01 “Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-OralImmunotherapy (SLIT) of Allergic Rhinoconjunctivitis with or Without Asthma Caused by Ragweed Pollen.”
J&J ALZA Protoco l C-2006-009 “A Phase IIA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of RWJ-445380 Cathepsin-s Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy.”
Novartis Pharmaceuticals Protocol CIGE025A US23 “A 26-week, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the effect of Xolair (omalizumab) on improving the tolerability of specific immunotherapy in patients with persistent allergic asthma.”
Olopatadine and Skin Testing” – A research study evaluating the effects of antihistamine eye drops on allergy skin testing.
Roche Protocol WA18696D “Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.”
VIRTUE Protocol 05-01-I: “A Phase IV Trial Evaluating Health Related Quality of Life and Serious Bacterial Infections in Subjects with Primary Immunodeficiency Disorder (PIDD) Treated